Influence of transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients

Cytokine

Volumn 60, Issue 1, 2012, Pages 271-276

  Radwan, Mohamed I ^a   Pasha, Heba F ^a   Mohamed, Rasha H ^b   Hussien, Hala I M ^a   El Khshab, Mohamed N ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Cirrhosis; Hepatitis c virus; Hepatocellular carcinoma; Transforming growth factor 1; Tumor necrosis factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUMOR NECROSIS FACTOR ALPHA GENE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS C VIRUS;

EID: 84865402736     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.010     Document Type: Article

References (46)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Zekri A.R., Bahnassy A.A., Abdel-Wahab S.A., Khafagy M.M., Loutfy S.A., Radwan H., et al. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients a associated with HCV-genotype-4. J Gastroenterol Hepatol 2009, 24:416-428.
3. Chiaramonte M., Stroffolini T., Vian A., Stazi M.A., Floreani A., Lorenzoni U., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999, 85:2132-2137.
4. Takano S., Yokosuka O., Imazeki F., Tagawa M., Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients. Hepatology 1995, 21:650-655.
5. Tarao K., Rino Y., Ohkawa S., Shimizu A., Tamai S., Miyakawa K., et al. Association between high serum alanine aminotransferase levels and more rapid development and higherrate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999, 86:589-595.
6. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
7. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006, 97:439-447.
8. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8:93-97.
9. Pulleyn L.J., Newton R., Adcock I.M., Barnes P.J. TGF beta1 allele association with asthma severity. Hum Genet 2001, 109:623.
10. Anderson G.M., Nakada M.T., DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004, 4:314-320.
11. Hajeer A.H., Hutchinson I.V. TNF-a gene polymorphism: clinical and biological implications. Microsc Res Technol 2000, 50:216-228.
12. Hajeer A.H., Hutchinson I.V. Influence of TNF alpha gene polymorphisms on TNF alpha production and disease. Hum Immunol 2001, 62:1191-1199.
13. Wilson A.G., di Giovine F.S., Blakemore A.I., Duff G.W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353-359.
14. Carturan S., Roccatello D., Menegatti E., Di Simone D., Davit A., Piazza A., et al. Association between transforming growth factor beta1 gene polymorphisms and IgA nephropathy. J Nephrol 2004, 17:786-793.
15. Ho S.Y., Wang Y.J., Chen H.L., Chen C.H., Chang C.J., Wang P.J., et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-a promoter gene. Cancer Causes and Control 2004, 15:657-663.
16. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
17. Weatherall D., Clegg J., Kwiatkowski D. The role of genomics in studying genetic susceptibility to infectious disease. Genome Res 1997, 7:967-973.
18. Gewaltig J., Mangasser-Stephan K., Gartung C., Biesterfeld S., Gressner A.M. Association of polymorphisms of the transforming growth factor-b1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002, 316:83-94.
19. Wang H., Mengsteab S., Tag C.G., Gao C.F., Hellerbrand C., Lammert F., et al. Transforming growth factor-b1 gene polymorphisms are associated with severity of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005, 11:1929-1936.
20. Wang H., Zhao Y.P., Gao C.F., Ji Q., Gressner A.M., Yang Z.X., et al. Transforming growth factor beta 1 gene variants increase transcription and are associated with liver cirrhosis in Chinese. Cytokine 2008, 43:20-25.
21. Verma V., Chakravarti A., Kar P. Cytokine levels of TGF-b, IL-10, and sTNFaRII in type C chronic liver disease. Dig Dis Sci 2008, 53:2233-2237.
22. Zekri A.R.N., Ashour M.S.E., Hasan A., Ei-Din H.M.A., Ei-Shehaby A.M.R., Abu-Shady M.A. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol 2005, 11:6624-6630.
23. Falleti E., Fabris C., Toniutto P., Fontanini E., Cussigh A., Bitetto D., et al. TGF-b1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine 2008, 44:256-261.
24. Qi P., Chen Y., Wang H., Fang M., Ji Q., Zhao Y., et al. 509C>T polymorphism in the TGF-_1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol Immunother 2009, 58:1433-1440.
25. Bissell D.M. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001, 33:179-190.
26. Taniguchi H., Kato N., Otsuka M., Goto T., Yoshida H., Shiratori Y., et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004, 72:52-931.
27. Szlosarek P.W., Balkwill F.R. Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 2003, 4:565-573.
28. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006, 4:221-233.
29. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42:745-750.
30. Knight B., Yeoh G.C.T., Husk K.L., Ly T., Abraham L.J., Yu C., et al. Imparied preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000, 192:1809-1818.
31. Talaat R.M. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol 2010, 2:151-157.
32. Talaat R.M., Esmail A.A., Elwakil R., Gurgis A.A., Nasr M.I. Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer 2012, 31:29-35.
33. Kishta S.A., Abd-Alhade A.A., Hamam O., Raoof E.A., Abeya S. Prognostic value of TNF a mRNA and VEGF mRNA expression in patients with chronic hepatitis C genotype-4, with and without cirrhosis and hepatocellular carcinoma to predict disease outcome. J Egypt Soc Parasitol 2010 Aug, 40(2):515-530.
34. Jeng J.E., Tsaiz J.F., Chuangb L.Y., Ho M.S., Linz Z.Y., Hsiehz M.Y., et al. Tumor necrosis factor-a 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma1. Neoplasia 2007, 9:987-992.
35. Akki{dotless}z H., Bayram S., Bekar A., özdil B., Akgöllü E., Sümbü A.T., et al. G-308A TNF-a polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 2009, 33:261-264.
36. Abraham L.J., Kroeger K.M. Impact of the _308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999, 66:562-566.
37. Isigkeit A.R., Hasselbach E., Ocklitz E., Brückner S., Ros A., Gehring H. Interindividual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol 2001, 125:80-88.
38. Gonzá lez S., Rodrigo L., Martíner-Borra J., Ló pez-Vázquez A., Fuentes D., Niño P., et al. TNF-a_308A promoter polymorphism is associated with enhanced TNFa production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003, 98:1101-1106.
39. Chuang E., Del Vecchio A., Smolinski S., Song X.Y., Sarisky R.T. Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense?. Trends Biotechnol 2004, 22:517-523.
40. Maki A., Kono H., Gupta M., Asakawa M., Suzuki T., Matsuda M., et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus - associated hepatocellular carcinoma. Ann Surg Oncol 2007, 14:1182-1190.
41. Giannelli G., Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 2005, 20:939-944.
42. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
43. Brechot C. Molecular mechanisms of hepatitis B and C viruses related to liver carcinogenesis. Hepatogastroenterol 1998, 45:1189-1196.
44. Mocellin S., Rossi C.R., Pilati P., Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005, 16:35-53.
45. Leibovich S.J., Polverini P.J., Shepard H.M., Wiseman D.M., Shively V., Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factoralpha. Nature 1987, 329:630-632.
46. Balasubramanian S.P., Brown N.J., Reed M.W.R. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002, 87:1057-1065.